Amaxa’s transfection technology and R&D site will grow Lonza’s business.

Lonza is acquiring amaxa to strengthen its cell-discovery business. The purchase will form a synergistic company with Lonza’s focus on primary cell production and amaxa’s expertise in transfection of primary cells.

Lonza says that the deal will enhance current margins and its growth rate. amaxa offers high-end nucleic acid transfection systems and consumables to academic institutions and pharmaceutical and biotechnology businesses. In particular, the company provides a technology called Nucleofection, which enables efficient and reproducible transfer of nucleic acids such as DNA or RNA into cells that are considered difficult or even impossible to transfect. according to the firm.

Additionally, Lonza notes that the amaxa purchase will bolster its R&D platform by tripling the size of the cell-discovery R&D group. amaxa’s Cologne site is planned to be a new product development site for the cell-discovery segment. The facility will also supplement the existing activities in Walkersville, MD.

The transaction is expected to take place early in the third quarter.

Previous articleInvestigators Discover Genetic Mutation Associated with Increased Risk of Lung Cancer
Next article3SBio Obtains Chinese License to AMAG’s Iron-Replacement Therapy